May 25 (Reuters) - Aroa Biosurgery Ltd (ARX) :
- FY22 PRODUCT SALES GUIDANCE OF $30M-33M
- TOTAL REVENUE FOR FY21 WAS $22.3M
- NORMALISED LOSS BEFORE INCOME TAX FOR FY21 WAS $7.4M
- PRODUCT GROSS MARGINS EXPECTED TO IMPROVE IN H2 FY22
News: ARX Aroa Biosurgery Posts FY22 Product Sales Guidance Of $30M-33M
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.0¢ |
Change
0.010(2.00%) |
Mkt cap ! $175.5M | |||
| Open | High | Low | Value | Volume |
| 53.5¢ | 53.5¢ | 49.0¢ | $51.73K | 103.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 600 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 51.0¢ | 8870 | 2 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
50.0¢ |
Change
0.010 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 52.5¢ | 53.5¢ | 48.5¢ | 60919 | ||
| Last updated 15.32pm 26/04/2024 ? | |||||
| ARX (ASX) Chart |